Recruiting
Phase 1

SynKIR-310 for Relapsed/Refractory B-NHL

Sponsor:

Verismo Therapeutics

Code:

NCT06544265

Conditions

B Cell Lymphoma

NHL, Adult

Mantle Cell Lymphoma

Relapsed Non-Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SynKIR-310

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Verismo Therapeutics on 2024-11-22.